Abbott (ABT)

• Market cap: $197B
• 1 day: -0.38%
• 5 days: 0.78%
• 1 month: 0.17%
• 3 months: -3.74%
• 6 months: 8.41%
• Year to date: 0.04%
• 1 year: -0.39%
• 5 years: 27.51%
• 10 years: 156.63%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

48% more first-time investments, than exits

New positions opened: 188 | Existing positions closed: 127

9% more funds holding in top 10

Funds holding in top 10: 58 [Q2] → 63 (+5) [Q3]

5% more capital invested

Capital invested by funds: $143B [Q2] → $150B (+$7.41B) [Q3]

4% more call options, than puts

Call options by funds: $1.1B | Put options by funds: $1.05B

1% more funds holding

Funds holding: 2,814 [Q2] → 2,840 (+26) [Q3]

3.15% less ownership

Funds ownership: 78.76% [Q2] → 75.6% (-3.15%) [Q3]

11% less repeat investments, than reductions

Existing positions increased: 1,050 | Existing positions reduced: 1,179

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $149 31% upside
• Avg. target: $149 31% upside
• High target: $149 31% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Barclays Matt Miksic 67% 1-year accuracy 24 / 36 met price target

31% upside $149

Overweight Maintained

5 Nov 2024